Overview
Zoey Xie is an associate in the Litigation Department of Paul Hastings. Zoey focuses her practice on FCPA/anti-corruption, internal and government investigations, sanctions, trade controls, cross-border data protection and dispute resolution. She also counsels life sciences companies on regulatory issues, including regulatory inspections, clinical trials and human genetic resource management. Zoey advises clients, including Chinese state-owned enterprises, across a variety of other industries, including life sciences, technology, manufacturing, financial services, luxury and telecommunication.
Prior to joining the firm, Zoey worked as an associate at two leading U.S. law firms in Shanghai.
Zoey is admitted to practice in New York. She passed the bar examination in China in 2011, but does not hold a current practicing certificate. Zoey is fluent in English and Mandarin.
Education
- Fordham School of Law, LL.M.
- Ningbo University, LL.B.
Representations
Investigations and Enforcement
- Represented a multinational software corporation in internal investigations of its operations in Greater China in connection with whistleblower allegations, bribery and corruption, revenue recognition and suspected fraudulent practices.
- Represented the independent audit committee of the board of directors of a U.S. public-listed Chinese corporation in an internal investigation into allegations of financial irregularities.
- Represented the independent audit committee of the board of directors of a U.S. public-listed Chinese corporation in an internal investigation into allegations of fraudulent practices.
- Represented a public-listed corporation in China in compliance risk assessment and compliance program testing in connection with its debarment by the Asian Development Bank for fraudulent practices.
- Represented a U.S. public-listed software company in an investigation from the Chinese government against its Chinese subsidiary triggered by an FCPA violation.
- Represented a multinational aerospace company in investigations from multiple governments related to allegations of fraudulent practices and noncompliant interactions with Chinese government officials through its business partners.
- Represented multinational pharmaceutical and medical device companies in internal investigations relating to suspected bribery misconduct, off-label promotion, sponsorships and grants, bid-rigging, and third party and distributor misconduct.
- Conducted post-closing compliance due diligence on revenue recognition issues on behalf of the Chinese shareholder of a Fortune 500 joint-venture telecommunication company.
Compliance and Risk Assessment
- Representation of Hong Kong IPO issuers and sponsors in connection with sanctions and trade controls matters.
- Represented an American multinational technology company on cross-border data transfer and data privacy issues regarding its internal medical institution in China.